Neurocrine Biosciences

Our Company

Neurocrine Biosciences of San Diego discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.

In the News
10/2/2014 Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
10/1/2014 Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer view all press releases


Webcast Webcast

Neurocrine frequently conducts webcasts and conference calls to provide presentations and company updates and progress on research and development activiites.

 view current webcasts 



New Data Our Corporation Presentation

This presentation provides an overview of our company pipeline, program process, and financial highlights.

/common/images/orangearrow.gif view the presentation



Stock Quote
Price Quote 16.32
Change -1.03
(20 minutes delayed)
 
Date
10/17/2014
Time
4:00 pm